HOME
Medis GmbH
campus 21, Europaring F15/301
A-2345 Brunn am Gebirge
Medis GmbH
campus 21, Europaring F15/301
A-2345 Brunn am Gebirge
Medis GmbH
campus 21, Europaring F15/301
A-2345 Brunn am Gebirge
Reimbursement of rare disease treatments in Cyprus is governed by the Cyprus Ministry of Health’s General Healthcare System (GHS), which provides universal healthcare coverage to all citizens and legal residents. The GHS covers the cost of medically necessary treatments for rare diseases, including medications, procedures, and medical devices.
To be eligible for reimbursement, rare disease treatments must be approved by the European Medicines Agency (EMA) or the Cyprus National Organization for Medicines (NOP). Once a treatment is approved, the manufacturer must apply for reimbursement by submitting a dossier to the GHS. The dossier must include evidence of the treatment’s safety, efficacy, and cost-effectiveness.
The reimbursement process can be complex, and it may take some time to receive approval. The GHS evaluates each application on a case-by-case basis and considers various factors, including the rarity of the disease, the severity of the condition, the availability of alternative treatments, and the cost of the treatment.
Once a treatment is approved for reimbursement, patients may need to pay a co-payment or deductible, depending on their income level and insurance coverage. However, the GHS provides financial assistance to low-income patients to help cover the cost of their treatment.
In summary, rare disease treatments in Cyprus are reimbursed through the GHS, which provides universal healthcare coverage to all citizens and legal residents. The reimbursement process requires approval from regulatory agencies, evidence of the treatment’s safety, efficacy, and cost-effectiveness, and may involve co-payments or deductibles for patients.
Proactive e-commerce via process-centric ‘outside the box“ thinking.
About us
Services
Location
Contact
Blog
Shop
Laboratory
Industry
Materials
Audio
Metallurgy
Video